Countdown to 2030: eliminating hepatitis B disease, China.
Liu J, Liang W, Jing W, Liu M. · 2019
Read Countdown to 2030: eliminating hepatitis B disease, China. by Liu J, Liang W, Jing W, Liu M. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6453311.txt.
Introduction
Liu and co-authors chart China's path to eliminating hepatitis B disease by 2030 and name the priorities still standing in the way. China carries the world's largest hepatitis B burden; globally the virus held 257 million people chronically infected in 2015 and kills about 887,000 a year. Three decades of vaccination cut new infections sharply.
Childhood coverage and timely birth-dose vaccination both exceed 95 percent, blocking mother-to-child transmission. Mortality is the stubborn target: a 65 percent reduction by 2030 demands better diagnosis and treatment capacity, lower patient costs, and one integrated system spanning prevention, screening, and lifelong care. The authors align their steps with the World Health Organization's global strategy.
Catalog record
| CREATOR | Liu J, Liang W, Jing W, Liu M. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Countdown to 2030: eliminating hepatitis B disease, China By Jue Liu, Wannian Liang, Wenzhan Jing, Min Liu Published in: Bulletin of the World Health Organization DOI: 10.2471/BLT.18.219469 ABSTRACT Abstract Hepatitis B virus (HBV) infection is a major public health problem worldwide. China has the world’s largest burden of HBV infection and will be a major contributor towards the global elimination of hepatitis B disease by 2030. The country has made good progress in reducing incidence of HBV infection in the past three decades. The achievements are mainly due to high vaccination coverages among children and high coverage of timely birth-dose vaccine for prevention of mother-to-child transmission of HBV (both > 95%). However, China still faces challenges in achieving its target of 65% reduction in mortality from hepatitis B by 2030. Based on targets of the World Health Organization’s Global health sector strategy on viral hepatitis 2016–2021, we highlight further priorities for action towards HBV elimination in China. To achieve the impact target of reduced mortality we suggest that the service coverage targets of diagnosis and treatment should be prioritized. First, improvements are needed in the diagnostic and treatment abilities of medical institutions and health workers. Second, the government needs to reduce the financial burden of health care on patients. Third, better coordination is needed across existing national programmes and resources to establish an integrated prevention and control system that covers prevention, screening, diagnosis and treatment of HBV infection across the life cycle. In this way, progress can be made towards achieving the target of eliminating hepatitis B in China by 2030. INTRODUCTION Hepatitis B virus (HBV) infection is a major public health problem worldwide. The World Health Organization (WHO) estimated that 257 million people were living with chronic HBV infection in 2015 and that hepatitis B results in 887 000 deaths every year worldwide.1,2 To take action on sustainable development goal 3.3 on combating hepatitis, the World Health Assembly approved the global health sector strategy to eliminate viral hepatitis as a public health threat by 2030, with a target of reducing new infections by 90% and mortality by 65%.3 According to the global strategy, elimination of hepatitis B disease requires synergy across five core interventions: (i) immunization against hepatitis B; (ii) prevention of mother-to-child transmission (PMTCT) of HBV; (iii) blood and injection safety; (iv) harm reduction services for people who inject drugs; and (v) increased testing and treatment.3 To evaluate the global strategy, WHO also proposed a monitoring and evaluation framework for hepatitis B with 10 core indicators (Fig. 1).4 [Figure: WHO evaluation framework for hepatitis B virus elimination] China has the world’s largest burden of HBV infection and will be a major contributor to the global elimination of hepatitis B by 2030.5,6 The country has made good progress in combating hepatitis B in the past three decades. However, with the largest population in the world (1.39 billion in 2017), the absolute number of HBV-infected people in China is large at around 70 million.7 China still faces challenges to achieving the goal of hepatitis B elimination by 2030.4 In this paper we summarize China’s achievements and gaps in progress towards elimination of hepatitis B by 2030. We highlight further priorities for action and make suggestions on the implementation roadmap for hepatitis B elimination in China. APPROACH We conducted an online search for articles published before 20 November 2018. We searched the PubMed®, EMBASE® and the Cochrane Library databases for English language articles and the China National Knowledge Infrastructure and Wanfang databases for Chinese language articles. We used the search terms “hepatitis B”, “elimination of hepatitis”, “epidemiology”, “vaccination”, “PMTCT”, “blood safety”, “safe injection”, “harm reduction”, “diagnosis” and “treatment.” We also reviewed reports and health statistical yearbooks from WHO, the Joint United Nations Programme on HIV/AIDS and the Chinese government published over the past three decades. We based our analysis on the core indicators of the framework of the WHO Monitoring and evaluation for viral hepatitis B and C evaluation4 and the targets of the Global health sector strategy on viral hepatitis 2016‒2021.3 PROGRESS Prevalence In the past three decades, China has changed from a highly endemic to an intermediate endemic area for HBV infection.7,8 According to the data from national surveys in China, the weighted prevalence of hepatitis B surface antigen (HBsAg) adjusted for people aged 1–59 years declined from 9.8% in 1992 to 7.2% in 2006.9 Weighted HBsAg prevalence among people aged 1–29 years declined during 1992–2006, from 10.1% to 5.5% and during 2006–2014, from 5.5% to 2.6%.8 At present, it is estimated that there are about 70 million HBsAg carriers (5–6% prevalence).7,10 Testing and diagnosis Testing and diagnosis of HBV infection is the gateway for patients to access both prevention and treatment services, and is a crucial component of an effective response to the hepatitis B epidemic.11 In 2017, China updated its national viral hepatitis prevention and control plan (2017–2020).12 To increase the coverage of testing, the Chinese government requires medical institutions to screen for hepatitis B in all pregnant women during antenatal care and in patients who are undergoing surgery, hospitalization, haemodialysis or invasive diagnosis and treatment.12 The coverage of diagnosis has been improved due to the increasing proportion of pregnant women attending antenatal care (from 69.7% of 11.75 million live births in 1992 to 96.6% of 18.47 million live births in 2016) and the number of surgeries among inpatients (from 14.0 million in 2002 to 50.8 million in 2016).13 In addition, China launched the national preconception health examination project in 2010 to provide free health check-ups for reproductive couples (including free HBV serological testing) in 100 counties and then expanded it nationally in 2013.14 A study in rural China reported that nearly 1 in 10 couples preparing for pregnancy (202 816 out of 1 936 801 couples) are either discordant or both positive for HBsAg.15 From 2010 to 2016, the Chinese government allocated 7.25 billion Chines yuan (¥; ¥ 1equivalent to 0.15 United States dollars) for the national preconception health examination project and screened around 60.5 million couples.16,17 Vaccination coverage To combat hepatitis B, the Chinese government has made timely vaccination on newborns and infants its highest priority.9 In 1992, China was among the first developing countries to enact a universal hepatitis B vaccination programme for newborns and infants.9 China has integrated hepatitis B vaccine into the national expanded programme on immunization and provided free vaccination since 2002.9 The Chinese government allocated approximately ¥ 5.3 billion for neonatal hepatitis B vaccination from 1992 to 2005 and ¥ 15 billion for the procurement of national immunization vaccines and syringes.18,19 From 2009 to 2011, a catch-up campaign was launched for children younger than 15 years, which succeeded in vaccinating nearly 68 million children.20 With the support of national financial funds, vaccination coverage has been effectively guaranteed. Reported coverage of three doses of hepatitis B for infants has increased from 30.0% in 1992 to 99.6% in 2015, and timely birth-dose coverage has increased from 22.2% in 1992 to 95.6% in 2015 (Fig. 2).20–24 Meanwhile, timely birth-dose coverage is also guaranteed by the high hospital delivery rate which has increased from 52.7% of live births in 1992 to 99.8% of live births in 2016.13 Hepatitis B three-dose coverage and timely birth-dose